Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OSTEOP
MCID: OST002
MIFTS: 76

Osteoporosis (OSTEOP)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Osteoporosis

About this section

MalaCards integrated aliases for Osteoporosis:

Name: Osteoporosis 57 12 74 73 36 54 6 42 44 15 37 62 39 17 71
Postmenopausal Osteoporosis 73 29 6 17 32
Osteoporosis, Postmenopausal 57 71
Osteoporosis, Involutional 57 13
Bone Mineral Density Quantitative Trait Locus; Bmnd 57
Bone Mineral Density Variation Qtl, Osteoporosis 57
Bone Mineral Density, Quantitative Trait Locus 39
Bone Mineral Density Quantitative Trait Locus 57
Osteoporosis, Postmenopausal, Susceptibility 57
Osteoporosis, Susceptibility to 57
Osteoporosis Postmenopausal 54
Involutional Osteoporosis 73
Osteoporosis, Senile 71
Senile Osteoporosis 73
Osteop 73
Bmnd 57

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
osteoporosis:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Fetal diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11476
OMIM® 57 166710
KEGG 36 H01593
ICD9CM 34 733.0
MeSH 44 D010024
NCIt 50 C3298
SNOMED-CT 67 156825006
SNOMED-CT via HPO 68 263681008 64859006
UMLS 71 C0029456 C0029458 C0029459
Sources

Summaries for Osteoporosis

About this section
MedlinePlus : 42 Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and fracture (break) easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include Getting older Being small and thin Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteoporosis, also known as postmenopausal osteoporosis, is related to osteoporosis, juvenile and bone mineral density quantitative trait locus 15, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Osteoporosis is COL1A1 (Collagen Type I Alpha 1 Chain), and among its related pathways/superpathways are Osteoclast differentiation and Mineral absorption. The drugs Pioglitazone and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include Bone, and related phenotype is osteoporosis.

Disease Ontology : 12 A bone resorption disease characterized by decreased density of normally mineralized bone which results in the thinning of bone tissue and decreased mechanical strength.

KEGG : 36 Osteoporosis is a common disease characterised by a generalised reduction in bone mineral density (BMD), microarchitectural deterioration of bone tissue and an increased risk of fracture. Since BMD values fall progressively with age, the prevalence of osteoporosis increases with age. It has been estimated that approximately 50% of all women will have osteoporosis by the age of 80. Studies in twins and families indicate that genetic factors play an important role in the regulation of BMD and other determinants of osteoporotic fracture risk. Osteoporosis is a polygenic disorder, determined by the effects of several genes, each with relatively modest effects. Population-based studies and case-control studies have similarly identified polymorphisms in several candidate genes that have been associated with bone mass or osteoporotic fracture, including the vitamin D receptor, oestrogen receptor and collagen gene. Bisphosphonates, and in some patients denosumab, are first-line drugs for osteoporosis.

UniProtKB/Swiss-Prot : 73 Osteoporosis: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs.

PubMed Health : 62 About osteoporosis: Having weak bones that easily break is a sign of osteoporosis. It is normal for your bones to become less dense as you grow older, but osteoporosis speeds up this process. This condition can particularly lead to problems in older age because broken bones do not heal as easily in older people as they do in young people, and the consequences are more serious. In general, osteoporosis is more common in women, and they often develop it at a younger age. Getting older does not mean that you will automatically develop osteoporosis, but the risk does increase with age. People over the age of 70 are more likely to have low bone density. Plus, the risk of falling increases in old age, which then also makes fractures more likely. But there are several things you can do to protect and strengthen your bones – even if you are already older.

Wikipedia : 74 Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural... more...

More information from OMIM: 166710
Sources

Related Diseases for Osteoporosis

About this section

Diseases in the Osteoporosis family:

Osteoporosis, Juvenile Juvenile Primary Osteoporosis
Lrp5-Related Primary Osteoporosis

Diseases related to Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1112)
# Related Disease Score Top Affiliating Genes
1 osteoporosis, juvenile 33.8 WNT1 LRP5 COL1A2 COL1A1
2 bone mineral density quantitative trait locus 15 33.7 PDLIM4 CALCR
3 bone mineral density quantitative trait locus 8 33.6 PDLIM4 CALCR BMND8
4 bone resorption disease 33.0 LRP5 ESR1 COL1A2 COL1A1 CALCR
5 bone disease 32.7 LRP5 ESR1 DANCR COL1A1
6 brittle bone disorder 32.0 WNT1 LRP5 COL1A2 COL1A1
7 hyperostosis 31.2 LRP5 COL1A2 COL1A1
8 scleroderma, familial progressive 31.0 COL1A2 COL1A1
9 van buchem disease 31.0 WNT1 LRP5 COL1A1
10 col1a1/2 osteogenesis imperfecta 30.8 COL1A2 COL1A1
11 endosteal hyperostosis, autosomal dominant 30.6 LRP5 COL1A2 COL1A1
12 marfan syndrome 30.4 ESR1 COL1A2 COL1A1
13 dentinogenesis imperfecta 30.4 WNT1 COL1A2 COL1A1
14 osteogenesis imperfecta, type iii 30.3 WNT1 COL1A2 COL1A1
15 osteogenesis imperfecta, type v 30.2 COL1A2 COL1A1
16 dental fluorosis 30.0 ESR1 COL1A2
17 osteoporosis-pseudoglioma syndrome 11.7
18 bone mineral density quantitative trait locus 9 11.7
19 bone mineral density quantitative trait locus 10 11.7
20 bone mineral density quantitative trait locus 11 11.7
21 bone mineral density quantitative trait locus 13 11.7
22 bone mineral density quantitative trait locus 14 11.7
23 bone mineral density quantitative trait locus 4 11.5
24 bone mineral density quantitative trait locus 5 11.5
25 bone mineral density quantitative trait locus 6 11.5
26 hajdu-cheney syndrome 11.5
27 glucocorticoid-induced osteoporosis 11.5
28 nephrolithiasis/osteoporosis, hypophosphatemic, 1 11.5
29 nephrolithiasis/osteoporosis, hypophosphatemic, 2 11.5
30 juvenile primary osteoporosis 11.5
31 hypophosphatemic nephrolithiasis/osteoporosis 11.3
32 osteoporosis and oculocutaneous hypopigmentation syndrome 11.3
33 bone mineral density quantitative trait locus 16 11.3
34 bone mineral density quantitative trait locus 18 11.2
35 rickets 11.1
36 premature menopause 11.1
37 werner syndrome 11.1
38 syndromic x-linked intellectual disability snyder type 11.1
39 multicentric osteolysis, nodulosis, and arthropathy 11.1
40 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 11.1
41 hyperparathyroidism 11.1
42 aromatase deficiency 11.1
43 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 11.0
44 winchester syndrome 11.0
45 bone mineral density quantitative trait locus 12 11.0
46 lysinuric protein intolerance 11.0
47 geroderma osteodysplasticum 11.0
48 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.0
49 mucolipidosis iii alpha/beta 11.0
50 nestor-guillermo progeria syndrome 11.0

Comorbidity relations with Osteoporosis via Phenotypic Disease Network (PDN): (show top 50) (show all 85)


Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Pulmonary Heart Disease
Chylomicron Retention Disease Conjunctivitis
Conn's Syndrome Cystitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Femoral Vein Thrombophlebitis Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hyperparathyroidism
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypothyroidism Idiopathic Interstitial Pneumonia
Inflammatory Bowel Disease 1 Intervertebral Disc Disease
Intestinal Obstruction Iron Deficiency Anemia
Irritable Bowel Syndrome Macular Degeneration, Age-Related, 1
Major Depressive Disorder Marasmus
Monoclonal Paraproteinemia Neurogenic Bladder
Nutritional Deficiency Disease Opioid Addiction
Oral Candidiasis Osteoarthritis

Graphical network of the top 20 diseases related to Osteoporosis:



Diseases related to Osteoporosis
Sources

Symptoms & Phenotypes for Osteoporosis

About this section

Human phenotypes related to Osteoporosis:

31
# Description HPO Frequency HPO Source Accession
1 osteoporosis 31 HP:0000939

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Skel:
postmenopausal osteoporosis

Clinical features from OMIM®:

166710 (Updated 05-Mar-2021)

UMLS symptoms related to Osteoporosis:


tremor, back pain, angina pectoris, sciatica, equilibration disorder, muscle cramp, pelvic pain
Sources

Drugs & Therapeutics for Osteoporosis

About this section

PubMed Health treatment related to Osteoporosis: 62

Even if someone already has osteoporosis , it is important for them to do regular exercise and get enough calcium and vitamin D . In Germany, statutory health insurances cover the cost of calcium or vitamin D supplements if a doctor has prescribed them. Osteoporosis can be treated with several drugs designed to slow bone loss and increase the production of new bone tissue . These include bisphosphonates and some hormonal or hormone -like medications. These kinds of drugs can have different types of side effects, though, and may not be suitable for everyone. They are only considered if someone has already broken a bone, or if their risk of bone fractures is high – for example, if their bone density is very low or if they have a combination of different risk factors, like low body weight, old age and a higher risk of falling . Hormone products, like those used to treat menopause symptoms , can also lower the risk of osteoporosis -related bone fractures when taken over the long term. But long-term hormone therapy during or after menopause increases the risk of cardiovascular diseases and breast cancer . For this reason it is only rarely recommended as treatment for osteoporosis. The pros and cons of this treatment should be carefully weighed.

Drugs for Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 392)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
9
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
10
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
11
Ribavirin Approved Phase 4 36791-04-5 37542
12
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
13
Gliclazide Approved Phase 4 21187-98-4 3475
14
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
15
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
16
Tibolone Approved, Investigational Phase 4 5630-53-5
17
Demeclocycline Approved Phase 4 127-33-3 5311063
18
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
19
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
22
Lactitol Approved, Investigational Phase 4 585-86-4 157355
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
25
tannic acid Approved Phase 4 1401-55-4
26
Sodium citrate Approved, Investigational Phase 4 68-04-2
27
Cinacalcet Approved Phase 4 226256-56-0 156419
28
Morphine Approved, Investigational Phase 4 57-27-2 5288826
29
Ibuprofen Approved Phase 4 15687-27-1 3672
30
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
31
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
32
Acetaminophen Approved Phase 4 103-90-2 1983
33
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
34
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
35
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
36 Abaloparatide Approved, Investigational Phase 4 247062-33-5
37
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
38
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
39
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
40
Pravastatin Approved Phase 4 81093-37-0 54687
41
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
42
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
43
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
44
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4 53-43-0 5881
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
47 Progestins Phase 4
48 HIV Protease Inhibitors Phase 4
49
protease inhibitors Phase 4
50 Phytoestrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 1339)
# Name Status NCT ID Phase Drugs
1 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
2 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
3 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
4 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
5 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
6 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
7 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
8 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
9 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
10 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
11 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
12 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
13 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
14 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
15 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
16 The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass Completed NCT02499237 Phase 4 Denosumab;Zoledronic acid
17 Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study Completed NCT02808988 Phase 4
18 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
19 Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid
20 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
21 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
22 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
23 OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study Completed NCT00592917 Phase 4
24 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
25 Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study Completed NCT00371956 Phase 4 raloxifene;placebo
26 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients - A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
27 A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg) Completed NCT00327990 Phase 4 Ibandronate;Alendronate
28 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
29 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
30 Fracture (FX) Improvement With Teriparatide: FiX-IT Study Completed NCT01705587 Phase 4 teriparatide
31 Antiepileptic Drugs and Osteoporotic Prevention Trial Completed NCT00869622 Phase 4 Risedronate;Placebo + Calcium and Vitamin D
32 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
33 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
34 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
35 Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures Completed NCT00271713 Phase 4 ibandronate, calcium and vitamin D;placebo,calcium and vitamin D
36 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
37 Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
38 Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes Completed NCT04149405 Phase 4 Bisphosphonate therapy
39 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed NCT02176382 Phase 4 denosumab;teriparatide;Zoledronic acid
40 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
41 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
42 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
43 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
44 A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis. Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
45 A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program Completed NCT00545363 Phase 4 Ibandronate
46 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
47 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
48 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
49 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
50 Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures Completed NCT01709110 Phase 4 Teriparatide;Risedronate;Placebo;Calcium;Vitamin D

Search NIH Clinical Center for Osteoporosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Alendronate
Calcitonin
calcium acetate
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium Citrate
calcium glubionate
Calcium gluceptate
Calcium Gluconate
CALCIUM GLUCONATE PWDR
Calcium Glycerophosphate
calcium lactate
CALCIUM LEVULINATE
Calcium Pantothenate
calcium phosphate
Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
pamidronate
Pamidronate Disodium
Raloxifene
Raloxifene Hydrochloride
Risedronate
risedronate sodium
salmon calcitonin
SODIUM FLUORIDE PWDR
Teriparatide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoporosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoporosis:
PREOB, autologous osteoblasts for bone disorders

Cochrane evidence based reviews: osteoporosis

Sources

Genetic Tests for Osteoporosis

About this section

Genetic tests related to Osteoporosis:

# Genetic test Affiliating Genes
1 Postmenopausal Osteoporosis 29 CALCR COL1A1 COL1A2 LRP5 PDLIM4
Sources

Anatomical Context for Osteoporosis

About this section

MalaCards organs/tissues related to Osteoporosis:

40
Bone, Bone Marrow, Prostate, Breast, Liver, Spinal Cord, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoporosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Mononucleated Osteoclasts Affected by disease
2 Bone Bone Marrow Multinucleated Osteoclasts Affected by disease
3 Blood Hematopoietic Bone Marrow Osteoclast Precursor Cells Affected by disease
Sources

Publications for Osteoporosis

About this section

Articles related to Osteoporosis:

(show top 50) (show all 32078)
# Title Authors PMID Year
1
Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. 57 54 61
19429913 2009
2
An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. 57 54 61
14671165 2003
3
Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. 61 54 57
10942433 2000
4
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. 61 57 54
8841196 1996
5
Genetics of osteoporosis. 61 57
16762578 2006
6
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. 54 57
15744038 2005
7
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. 61 57
14602752 2003
8
Genetic control of susceptibility to osteoporosis. 61 57
12050200 2002
9
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. 61 57
11889149 2002
10
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. 61 57
11701687 2001
11
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. 61 57
11344179 2001
12
The genetics of osteoporosis: 'complexities and difficulties'. 57 61
10782923 2000
13
The genetic trail of osteoporosis. 61 57
9535673 1998
14
Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. 61 57
8053404 1994
15
Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. 61 6
2052622 1991
16
Reduced bone mass in daughters of women with osteoporosis. 57 61
2915666 1989
17
Implementation of a fracture liaison service for patients with hip fracture cared for on a hospital medicine service. 61 42
33023365 2021
18
Experiences of using an activating spinal orthosis in women with osteoporosis and back pain in primary care. 61 42
33123853 2020
19
Identification of osteoporosis markers through bioinformatic functional analysis of serum proteome. 61 42
32991410 2020
20
Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. 57
26367794 2015
21
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. 57
22504420 2012
22
Multiple genetic loci for bone mineral density and fractures. 57
18445777 2008
23
Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. 57
17264806 2007
24
Interspecies synteny mapping identifies a quantitative trait locus for bone mineral density on human chromosome Xp22. 57
16183656 2005
25
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. 57
15908955 2005
26
The effect of calcium supplementation on bone density in premenarcheal females: a co-twin approach. 57
15472185 2004
27
Interaction between vitamin D receptor genotype and estrogen receptor alpha genotype influences vertebral fracture risk. 57
12915669 2003
28
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 57
12908099 2003
29
Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. 57
11061497 2000
30
Vitamin D supplementation in postmenopausal black women. 57
10566638 1999
31
Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. 57
9535665 1998
32
Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes. 6
8786074 1996
33
Partial isodisomy for maternal chromosome 7 and short stature in an individual with a mutation at the COL1A2 locus. 6
1463018 1992
34
Estrogen status and heredity are major determinants of premenopausal bone mass. 57
1469098 1992
35
Genetic determinants of bone mass in adults. A twin study. 57
3624485 1987
36
Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. 54 61
20184423 2010
37
The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. 54 61
20197302 2010
38
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 61 54
20189618 2010
39
Osteocalcin gene polymorphisms influence concentration of serum osteocalcin and enhance fracture identification. 61 54
20200947 2010
40
Effect of glucocorticoid-, parathyroid- and thyroid hormones excess on human iliac crest bone matrix insulin-like growth factor (IGF)-I in patients with osteoporosis. 61 54
19998242 2010
41
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. 54 61
19874198 2010
42
New treatment targets in osteoporosis. 54 61
20381400 2010
43
Biochemical mechanism of gallium on prevention of fatal cage-layer osteoporosis. 54 61
19639269 2010
44
The association of serum osteoprotegerin and osteoporosis in postmenopausal hemodialysis patients: a pilot study. 61 54
20210559 2010
45
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. 61 54
20079640 2010
46
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. 61 54
20116187 2010
47
Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. 54 61
19673927 2010
48
[Effects of SERMs on bone health. SERM actions other than on the bones. With special reference to the actions of SERM on the skin and vascular elasticity]. 61 54
20190369 2010
49
Genetics of osteoporosis: accelerating pace in gene identification and validation. 61 54
20101412 2010
50
Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome. 61 54
20096619 2010